Primary responsibilities will
include drug therapy...
Treatment of destructive behavior in dogs will include specific training or behavioral modification techniques and may
include drug therapy.
Provided service to assisted - living facilities,
including drug therapy review and blister - packs.
Not exact matches
Approved treatments
included gene
therapies and the first new
drugs for rare diseases in many years.
Swiss pharmaceutical giant Novartis has made waves with a
drug pipeline that
includes one of the most talked - about experimental cancer
therapies in recent years — a treatment called Kymriah that reconfigures the body's own immune cells to become aggressive blood - cancer killers.
giant Novartis has made waves with a
drug pipeline that
includes one of the most talked - about experimental cancer
therapies in recent years — a treatment called Kymriah that reconfigures the body's own immune cells to become aggressive blood - cancer killers.
These risks and uncertainties
include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products,
including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS
Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the S
Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell
therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new
drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the S
drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products,
including Biktarvy; Gilead's ability to successfully commercialize its products,
including Biktarvy; the risk that physicians and patients may not see advantages of these products over other
therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates,
including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
But I think it is long past time to consider the value of other approaches,
including the targeted use of
drug therapies.
There's a risk that honey can interfere with some
drugs or
therapies,
including some chemotherapy
drugs.
Thousands of deaths could be averted through a combined prevention and treatment strategy — interventions such as improved mother and child nutrition, optimal breastfeeding practices; Oral Rehydration
Therapy [ORT]; new low - osmolarity formulations of ORS; incorporating rotavirus vaccines; zinc supplementation during diarrhoea episodes; immunizing all children against measles; appropriate drug therapy; increased access to safe clean water and sanitation facilities and improved personal and domestic hygiene, including keeping food and water clean and washing hands before touchin
Therapy [ORT]; new low - osmolarity formulations of ORS; incorporating rotavirus vaccines; zinc supplementation during diarrhoea episodes; immunizing all children against measles; appropriate
drug therapy; increased access to safe clean water and sanitation facilities and improved personal and domestic hygiene, including keeping food and water clean and washing hands before touchin
therapy; increased access to safe clean water and sanitation facilities and improved personal and domestic hygiene,
including keeping food and water clean and washing hands before touching food.
Those changes
include pressing for more insurance coverage for more outpatient
drug rehabilitation
therapies.
The decline was highlighted by Cuomo last year when he announced plans for his End the Epidemic initiative, which
included assisting undiagnosed HIV patients find health care, getting patients on anti-HIV
therapy and providing high - risk people with HIV prevention
drugs.
Since the neuronal death can be recapitulated in directly reprogrammed patient neurons, Yoo said the new technique offers a way to study the details of how potential
therapies —
including drugs that are currently being tested in clinical trials — could rescue medium spiny neurons from death.
Unlike many clinical trials that emphasize relief of symptoms as their primary objective, the ezogabine study's goal is to gauge how well the
therapy addresses some of the biological underpinnings of depression — in this case, whether the
drug lessens the hyperactivity of the reward circuit that
includes VTA neurons.
In Solms and Panksepp's vision of the future, depression treatment might blend various types of
therapy — sometimes
including psychoanalysis — with
drug regimens designed to target the neural circuitry involved in a well - understood emotional response.
Today, alternative
therapies including traditional Chinese herbal medicines (TCHM) have achieved astonishing popularity even though they are not encouraged by the U.S. Food and
Drug Administration, which classifies most plant
drugs as dietary supplements or food additives and also places severe limitations on labelling.
In science news around the world, NASA's Cassini mission is about to take its final plunge into the atmosphere of Saturn after 13 years providing an unprecedented view of the planet and its moons, a fight over whether to preserve or develop of one Europe's oldest gold mining sites heats up again, the U.S. Food and
Drug Administration approves the first cancer gene
therapy for people, a U.S. court gives a green light to a $ 1 billion lawsuit brought by the Guatemalan victims and survivors of mid — 20th century syphilis experiments by research institutions
including Johns Hopkins University, and more.
The Mast Cells and Basophiles: Targets for Innovative
Therapies project, funded by COST funding BM1007 of the EU, brings together European experts focusing on the identification of new target molecules for
drug development,
including allergy
drugs.
The journal provides cutting - edge research
including results from animal models that are likely to apply to patients, studies in human tissue that provide new information about
therapies or disease, and innovative reports of
drug discovery and development.
Celgene scientist Patrick Hagner develops next - generation IMiD
therapies,
including drug candidate CC122.
These
include the ability to bring new, innovative products to the market; progress in oncology, such as the approval of Genentech's
drug Avastin for breast cancer and advances in the use of gene
therapy, despite some setbacks; continuing progress in research on stem cells; the emergence of treatments for previously untreated diseases; and solutions for food and fuel shortages, such as biocrops and biofuels.
And last month, at the annual J.P. Morgan Healthcare Conference in San Francisco, California, CEO Stéphane Bancel unveiled Moderna's first round of
drug candidates, which
include vaccines for Zika and flu, and a
therapy for heart failure.
Biopharmaceutical
drugs, which are used in a wide range of
therapies including vaccines and treatments for diabetes and cancer, are typically produced in large, centralized fermentation plants.
The methods might
include drugs to slow the loss of connections between neurons, as well as cognitive and behavioral
therapies designed to strengthen imperfect circuits.
The trial investigated the
drug in two separate cohorts of patients: Cohort A, which
included 170 patients with heavily pretreated metastatic triple negative breast cancer (mTNBC) regardless of PD - L1 expression, and Cohort B, which
included 52 patients with PD - L1 - positive tumors who received it as first - line
therapy.
Enzalutamide, which is taken as four pills once per day, is already approved by the Food and
Drug Administration (FDA) for men whose disease has not been stopped by other treatments
including, surgery, radiation, androgen deprivation
therapy and chemotherapy.
Inhibitory control Other strategies being pursued to prevent the formation of inhibitors of clotting - factor
therapy include immunosuppressants and
drugs that deplete specific immune cells.
Advances in understanding the cells and molecules that transmit pain signals are providing new targets for
drugs that could relieve various kinds of pain —
including those poorly controlled by existing
therapies
Items worthy of mention in this context
include new
drugs for cancer, new
therapies for rare diseases, progress in HIV medications, and stem cell research.
Celgene's pipeline
includes several oral
drugs for solid tumors and hematologic cancers and cellular
therapies for Crohn's disease, multiple sclerosis, rheumatoid arthritis, and sarcoidosis.
The discovery also represents a major advance in understanding why many tissues in humans,
including limb tissue, regenerate poorly — and in being able to possibly manipulate those mechanisms with
drug therapies.
And up to half of participants enrolled in clinical trials to treat PTSD fail to respond to
therapies including serotonin - reuptake inhibitors — a class of
drugs often used as antidepressants — and cognitive behavioural
therapy.
This has applications in the manufacturing of new chemical products that can be used in industry,
including new
drugs for cancer
therapy and new electronics for computers.
A University of Colorado Cancer Center study published in the journal Breast Cancer Research and Treatment shows that breast cancer patients whose health insurance plans
included prescription
drug benefits were 10 percent more likely to start important hormonal
therapy than patients who did not have prescription
drug coverage.
In the Cancer Cell article, the researchers describe how various anticancer
drugs,
including cisplatin and the targeted
therapy vemurafenib, which targets melanomas with the BRAF mutation, become more effective when co-delivered with phenformin.
That is, they contained multiple populations of cells,
including the so - called JARID1B cells, which their research suggested was responsible for allowing tumors to survive
drug therapy.
Human proteins rarely mutate to a significant extent, so HIV will be far less likely get around
drug combination
therapies that
include a CXCR4 / CCR5 inhibitor, Liotta explains.
All patients also received standard medical
therapy throughout the trial, which in a vast majority of cases
included treatment with statins or other cholesterol - lowering
drugs.
Future areas of research
include developing a deeper understanding of exactly how these
drugs work under different conditions to ultimately help with development of new, better tolerated anti-inflammatory
therapies.
Raydiance's technology has attracted the attention of the U.S. Food and
Drug Administration (FDA), which in July 2007 signed the company to a two - year cooperative research and development agreement that has allowed the FDA's Center for Devices and Radiological Health (CDRH) to evaluate the use, safety and effectiveness of Raydiance's USP laser system in a number of areas,
including the ablation of corneal tissues in refractive surgery and corneal repair; the administration of light
therapy for treating cancer, cardiovascular disease and diabetes; and the removal of plaque on teeth without damaging the enamel.
The agency has also been promised an extra $ 101 million to help improve the safety of
drugs, devices, blood, and medical
therapies,
including efforts to bolster safety of cord blood and human tissue for transplant.
The costs of
drug therapy were analysed as overall costs, and the costs of hospital days were calculated according to the Finnish health care system's unit costs, which also
include the patient's payment contribution.
The biggest UK employers in industry are Smith & Nephew, a research company focused on wound care, and
drug company Pfizer, whose research
includes developing stem cell
therapies for Crohn's disease.
Many standard cancer treatments,
including chemotherapy
drugs and radiation
therapy, damage the DNA of rapidly dividing cancer cells.
These first - generation direct - acting antivirals are the first of many direct acting antiviral
drugs which will revolutionise treatment for HCV patients,
including those who failed to respond to previous
therapies.
It may also lead to improved
therapies to fight sleeping sickness; current medications used to combat the disease have improved over the past decade but still
include an old arsenic - based
drug that kills between 5 and 10 percent of the people receiving treatment, said the study's senior author Stephen Hajduk, a professor of biochemistry and molecular biology in the UGA Franklin College of Arts and Sciences.
The results, adds Muñoz, may also speed the search for
drug therapies for conditions where the senses are disrupted,
including Alzheimer's disease, schizophrenia, and autism.
Targeted
therapies, which are
drugs that interfere with specific molecules involved in cancer growth, have been successfully used in the treatment of many cancers,
including breast and blood cancers.
These should
include statins to lower cholesterol, and the multiple
drug therapies likely to be necessary to achieve control of high blood pressure, research suggests.
«With emphasis on reaching a targeted low - disease activity state, physicians have many
drugs to choose from for treating RA patients
including triple
therapy.